Tekni-Plex Acquires Johnson Plastic Group

Acquisition expands Tekni-Plex Healthcare's medical device capabilities and broadens the division's global footprint by adding a presence in Mexico.

Tekni-Plex Healthcare has acquired precision extrusion manufacturer Johnson Plastic Group (JPG) as part of a strategy to expand the company’s patient care solutions platform.

Located in Mexicali, Mexico, Johnson Plastic Group specializes in precision extrusions for medical device applications. The company provides complete extrusion solutions into a variety of medical device applications for interventional and therapeutic procedures.

The acquisition expands Tekni-Plex Healthcare’s medical device capabilities and broadens the division’s global footprint by adding a presence in Mexico.

“This acquisition makes total sense for us and improves our ability to service our customers,” said Chris Qualters, CEO of Tekni-Plex Healthcare. “It builds upon our existing solutions capabilities and increases our geographic reach, bringing us close to our key customer base in Mexico and the Baja region. It also allows us to leverage JPG’s expertise across our entire global customer base and healthcare end markets.”

Qualters noted: “The addition of JPG continues to build upon our innovative patient care solutions platform centered on material science and process technologies. We are looking forward to creating an even more robust set of offerings and solutions that help improve patient outcomes.”

Enrique Preciado, JPG owner and general manager, said: “We are truly excited to become part of Tekni-Plex Healthcare.  We now will be able to provide even greater opportunities for our employees and a broader range of products and material science solutions for our customers.”

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.